Primal Study
Precision Medicine Randomized Clinical Trial Comparing
Molecular Tumor Board Assisted Care to Usual Care (PRiMAL)
NCT05254795
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Past issues of the PRiMAL Newsletter are available in the archives.
- Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice (PMID: 37370804)
- Bridging the Biomarker Chasm With Interprofessional Molecular Tumor Boards (PMID: 37335966)
- Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial (PMID: 36103643)
- Clinical Outcomes of Molecular Tumor Boards: A Systematic Review (PMID: 34632252)
- Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer (PMID: 36422117)
- EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky (PMID: 32810185)
- Principal Investigator and Study Chair
- Lora Maynard, RN
Project Manager
Email: Lora.Maynard@uky.edu
- Kelly Tucker, RN, BSN, OCN
MTB Nurse Navigator
Email: Kelly.Tucker@uky.edu
- Noah Franklin
Clinical Research Associate I
Email: Noah.Franklin@uky.edu
- Maggie Spencer
Clinical Research Associate I
Email: Margaret.Spencer@uky.edu
- Hannah Craig
Clinical Research Associate I
Email: Hannah.Craig@uky.edu
UPCOMING MEETINGS
9th Annual Precision Medicine Symposium
Date TBA | Griffin Gate Marriott Resort and Spa
This symposium highlights clinical advances in precision medicine and cancer health disparities.
